Zlotta AR - Search Results

1

Concordance between transrectal ultrasound guided biopsy results and radical prostatectomy final pathology: Are we getting better at predicting final pathology?

Walker R, Lindner U, Louis A, Kalnin R, Ennis M, Nesbitt M, van der Kwast TH, Finelli A, Fleshner NE, Zlotta AR, Jewett MA, Hamilton R, Kulkarni G, Trachtenberg J. Walker R, et al. Among authors: zlotta ar. Can Urol Assoc J. 2014 Jan-Feb;8(1-2):47-52. doi: 10.5489/cuaj.751. Can Urol Assoc J. 2014. PMID: 24578745 Free PMC article.

2

Prostate cancer prevention: past, present, and future.

Fleshner N, Zlotta AR. Fleshner N, et al. Among authors: zlotta ar. Cancer. 2007 Nov 1;110(9):1889-99. doi: 10.1002/cncr.23009. Cancer. 2007. PMID: 17893870 Free article. Review.

3

Pharmacotherapy for prostate cancer: the role of hormonal treatment.

Shahani R, Fleshner NE, Zlotta AR. Shahani R, et al. Among authors: zlotta ar. Discov Med. 2007 Aug;7(39):118-24. Discov Med. 2007. PMID: 18093474 Free article.

4

Extended pattern prostate biopsy does not minimize the volume-grade bias in prostate cancer detection.

Al-Ghamdi AM, Lockwood G, Toi A, Kulkarni GS, Evans A, Finelli A, Zlotta AR, Fleshner N. Al-Ghamdi AM, et al. Among authors: zlotta ar. J Urol. 2008 Apr;179(4):1332-4. doi: 10.1016/j.juro.2007.11.067. Epub 2008 Mar 4. J Urol. 2008. PMID: 18289588

5

The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.

Musquera M, Fleshner NE, Finelli A, Zlotta AR. Musquera M, et al. Among authors: zlotta ar. Expert Rev Anticancer Ther. 2008 Jul;8(7):1073-9. doi: 10.1586/14737140.8.7.1073. Expert Rev Anticancer Ther. 2008. PMID: 18588452 Clinical Trial.

6

Thirty-five years of noninvasive bladder carcinoma: a plea for the use of papillary intraurothelial neoplasia as new terminology.

Van der Kwast TH, Zlotta AR, Fleshner N, Jewett M, Lopez-Beltran A, Montironi R. Van der Kwast TH, et al. Among authors: zlotta ar. Anal Quant Cytol Histol. 2008 Dec;30(6):309-15. Anal Quant Cytol Histol. 2008. PMID: 19160695

7

The burden of prostate cancer in Canada.

Fradet Y, Klotz L, Trachtenberg J, Zlotta A. Fradet Y, et al. Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S92-S100. Can Urol Assoc J. 2009. PMID: 19543427 Free PMC article.

8

Gleason grading controversies: what the chemoprevention trials have taught us.

Klotz L, Drachenberg D, Fradet Y, Saad F, Trachtenberg J, Zlotta A. Klotz L, et al. Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S115-20. doi: 10.5489/cuaj.1115. Can Urol Assoc J. 2009. PMID: 19543430 Free PMC article.

9

The fate of an unsatisfactory urine cytology test among patients with urothelial carcinoma.

Ordon M, Boerner S, Zlotta AR, Jewett MA, Fleshner N. Ordon M, et al. Among authors: zlotta ar. BJU Int. 2009 Dec;104(11):1641-5. doi: 10.1111/j.1464-410X.2009.08650.x. Epub 2009 Jul 2. BJU Int. 2009. PMID: 19583723

10

An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer.

Kulkarni GS, Hakenberg OW, Gschwend JE, Thalmann G, Kassouf W, Kamat A, Zlotta A. Kulkarni GS, et al. Eur Urol. 2010 Jan;57(1):60-70. doi: 10.1016/j.eururo.2009.08.024. Epub 2009 Sep 1. Eur Urol. 2010. PMID: 19740595 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

268 results

Search Page

Filters